ERBB2 and breast carcinoma: Regarding HER2‐/HoR+breast carcinoma, most of the clinicopathological parameters indicated favorable prognosis compared to HER2+/HoR‐ subtype, including age (P < 0.001), histological grade (P < 0.001), AJCC stage (P < 0.001), and N‐stage (P < 0.001).